Eli Lilly and Company

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Investigation Details

On May 1, 2025, Eli Lilly issued a press release reporting first quarter 2025 results and reaffirming guidance. In conjunction with this press release, Eli Lilly management commented on the decision made by CVS, one of the country’s largest pharmacies, to drop coverage for its popular weight-loss drug, Zepbound, in favor of competitor’s Wegovy. Notably, Eli Lilly’s CEO attributes 45% of the Company’s year-over-year revenue growth to strong sales of Zepbound and Mounjaro.

Following this news, Eli Lilly’s stock price fell by $104.85 per share, or approximately 11.7% to close at $794.10 per share.